Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received an average rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $59.73.

A number of research firms have recently issued reports on ARVN. Truist Financial reiterated a “buy” rating and set a $65.00 price target on shares of Arvinas in a research report on Monday, March 25th. Wedbush lifted their price target on shares of Arvinas from $33.00 to $59.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Oppenheimer reiterated an “outperform” rating and set a $80.00 price target (down from $95.00) on shares of Arvinas in a research report on Wednesday, February 28th. Citigroup downgraded shares of Arvinas from a “buy” rating to a “neutral” rating and lifted their price target for the company from $36.00 to $55.00 in a research report on Wednesday, February 14th. Finally, HC Wainwright reduced their price target on shares of Arvinas from $90.00 to $87.00 and set a “buy” rating for the company in a research report on Friday, April 12th.

Arvinas Stock Down 2.9 %

Shares of NASDAQ:ARVN opened at $31.60 on Friday. The company has a market cap of $2.16 billion, a P/E ratio of -4.86 and a beta of 1.94. Arvinas has a 52 week low of $13.57 and a 52 week high of $53.08. The company has a 50-day moving average price of $42.34 and a 200 day moving average price of $34.48.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.38). The firm had revenue of ($43.10) million during the quarter, compared to analyst estimates of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative return on equity of 70.24%. During the same quarter in the previous year, the business earned ($1.56) EPS. Analysts expect that Arvinas will post -5.02 EPS for the current year.

Insiders Place Their Bets

In other Arvinas news, insider Ronald Peck sold 1,699 shares of Arvinas stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $79,937.95. Following the completion of the sale, the insider now directly owns 67,516 shares of the company’s stock, valued at approximately $3,176,627.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Arvinas news, CFO Sean A. Cassidy sold 1,702 shares of Arvinas stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total value of $80,079.10. Following the completion of the sale, the chief financial officer now directly owns 181,916 shares of the company’s stock, valued at approximately $8,559,147.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ronald Peck sold 1,699 shares of Arvinas stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the sale, the insider now directly owns 67,516 shares of the company’s stock, valued at $3,176,627.80. The disclosure for this sale can be found here. In the last three months, insiders sold 8,597 shares of company stock valued at $404,489. Company insiders own 5.23% of the company’s stock.

Institutional Trading of Arvinas

Several institutional investors have recently made changes to their positions in ARVN. AE Wealth Management LLC purchased a new stake in shares of Arvinas during the 3rd quarter valued at $464,000. Mach 1 Financial Group LLC acquired a new position in shares of Arvinas during the 3rd quarter valued at $463,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Arvinas by 17.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 16,928 shares of the company’s stock valued at $332,000 after acquiring an additional 2,454 shares in the last quarter. BluePath Capital Management LLC acquired a new position in shares of Arvinas during the 3rd quarter valued at $28,000. Finally, Strs Ohio lifted its holdings in shares of Arvinas by 67.6% during the 3rd quarter. Strs Ohio now owns 29,000 shares of the company’s stock valued at $569,000 after acquiring an additional 11,700 shares in the last quarter. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.